METABOLIC SYNDROME, DYSLIPOPROTEINEMIA AND MELATONIN
DOI:
https://doi.org/10.32782/2226-2008-2024-2-9Keywords:
metabolic syndrome, obesity, dyslipoproteinemia, melatonin.Abstract
The metabolic syndrome (MetS) is a cluster of cardiovascular disease risk factors that includes obesity, dyslipoproteinemia, chronic lowintensity inflammation, oxidative stress, and insulin resistance. Research goal. The objective of the present study was to examine the particular features of melatonin’s impact on lipid metabolism in individuals with dyslipoproteinemias, both in experimental and clinical settings. We aim to evaluate whether melatonin can be used as a supplementary medication for the treatment of metabolic syndrome. Materials and methods. We conducted the analysis of the latest scientific research available in Scopus, Science Direct (published by Elsevier), PubMed, and Medline databases. Research results. The successful treatment of MetS requires a potential medication with antagonistic properties against the triggers of MetS. Deficiency of melatonin production or impaired expression of neurohormone receptors are associated with obesity, hypertension, and type 2 diabetes mellitus. In particular, there is a significant correlation between the levels of melatonin and insulin in patients with MetS, as well as between the melatonin/insulin ratio and changes in the blood lipid profile. The review focuses on describing the specific mechanisms of action of melatonin on lipid metabolism, as well as analyzing evidence from experimental and clinical trials of melatonin.
References
Cherkas A, Eckl P, Gueraud F et al. Helicobacter pylori in sedentary men is linked to higher heart rate, sympathetic
activity, and insulin resistance but not inflammation or oxidative stress. Croat Med J. 2016; 57(2): 141–149. doi: 10.3325/
cmj.2016.57.141.
Ziegler D, Porta M, Papanas N et al. The role of biofactors in diabetic microvascular complications. Curr Diabetes Rev.
; 18(4): e250821195830. doi: 10.2174/1871527320666210825112240.
Serhiyenko VA, Serhiyenko LM, Sehin VB, Serhiyenko AA. Pathophysiological and clinical aspects of the circadian rhythm
of arterial stiffness in diabetes mellitus: A minireview. Endocr Regul. 2022; 56(4): 284–294. doi: 10.2478/enr-2022-0031.
Donohoe F, Wilkinson M, Baxter E, Brennan DJ. Mitogen-activated protein kinase (MAPK) and obesity-related cancer. Int
J Mol Sci. 2020; 21(4): 1241. doi: 10.3390/ijms21041241.
Moschonis G, Trakman GL. Overweight and obesity: the interplay of eating habits and physical activity. Nutrients. 2023;
(13): 2896. doi: 10.3390/nu15132896.
Abood SJ, Abdulsahib WK, Hussain SA, Ismail SH. Melatonin potentiates the therapeutic effects of metformin in women
with metabolic syndrome. Sci Pharm. 2020; 88(2): 28. doi: 10.3390/scipharm88020028.
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. Focus (Am
Psychiatr Publ). 2018; 16(1): 113–118. doi: 10.1176/appi.focus.16101.
Ahmad SB, Ali A, Bilal M et al. Melatonin and health: Insights of melatonin action, biological functions, and associated
disorders. Cell Mol Neurobiol. 2023; 43(6): 2437–2458. doi: 10.1007/s10571-023-01324-w.
Wang L, McFadden JW, Yang G et al. Effect of melatonin on visceral fat deposition, lipid metabolism and hepatic lipometabolic
gene expression in male rats. J Anim Physiol Anim Nutr (Berl). 2021; 105: 787–796. doi: 10.1111/jpn.13497.
Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J. Regulation of cholesterol homeostasis in health and diseases: from
mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022; 7: 265. doi: 10.1038/s41392-022-01125-5.
Mi Y, Tan D, He Y, Zhou X, Zhou Q, Ji S. Melatonin modulates lipid metabolism in HepG2 cells cultured in high
concentrations of oleic acid: AMPK pathway activation may play an important role. Cell Biochem Biophys. 2018; 76(4):
–470. doi: 10.1007/s12013-018-0859-0.
Karolczak K, Watala C. The mystery behind the pineal gland: melatonin affects the metabolism of cholesterol. Oxid Med
Cell Longev. 2019; 2019: 4531865. doi: 10.1155/2019/4531865.
Hong F, Pan S, Xu P et al. Melatonin orchestrates lipid homeostasis through the hepatointestinal circadian clock and
microbiota during constant light exposure. Cells. 2020; 9(2): 489. doi: 10.3390/cells9020489.
Li Y, Ma J, Yao K et al. Circadian rhythms and obesity: Timekeeping governs lipid metabolism. J Pineal Res. 2020; 69(3):
e12682. doi: 10.1111/jpi.12682.
Martín V, Sanchez-Sanchez AM, Herrera F et al. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel
mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer. 2013; 108(10): 2005–2012. doi:
1038/bjc.2013.188.
Kaddah S, Khreich N, Kaddah F, Charcosset C, Greige-Gerges H. Cholesterol modulates the liposome membrane fluidity
and permeability for a hydrophilic molecule. Food Chem Toxicol. 2018; 113: 40–48. doi: 10.1016/j.fct.2018.01.017.
Čejková S, Králová-Lesná I, Poledne R. Monocyte adhesion to the endothelium is an initial stage of atherosclerosis
development. Cor Vasa. 2016; 58(4): e419–e425. doi: 10.1016/j.crvasa.2015.08.002.
Cherkas A, Abrahamovych O, Golota S et al. The correlations of glycated hemoglobin and carbohydrate metabolism
parameters with heart rate variability in apparently healthy sedentary young male subjects. Redox Biol. 2015; 5: 301–307.
doi: 10.1016/j.redox.2015.05.007.
Serhiyenko V, Serhiyenko A, Segin V, Serhiyenko L. Association of arterial stiffness, N-terminal pro-brain natriuretic
peptide, insulin resistance, and left ventricular diastolic dysfunction with diabetic cardiac autonomic neuropathy. Vessel
Plus. 2022; 6: 11. doi: 10.20517/2574-1209.2021.83.
Choi Y, Attwood SJ, Hoopes MI, Drolle E, Karttunen M, Leonenko Z. Melatonin directly interacts with cholesterol and
alleviates cholesterol effects in dipalmitoylphosphatidylcholine monolayers. Soft Matter. 2014; 10(1): 206–213. doi:
1039/C3SM52064A.
Hevia D, González-Menéndez P, Quiros-González I et al. Melatonin uptake through glucose transporters: a new target for
melatonin inhibition of cancer. J Pineal Res. 2015; 58(2): 234–250. doi: 10.1111/jpi.12210.
Ou TH, Tung YT, Yang TH, Chien YW. Melatonin improves fatty liver syndrome by inhibiting the lipogenesis pathway in
hamsters with high-fat diet-induced hyperlipidemia. Nutrients. 2019; 11(4): 748. doi: 10.3390/nu11040748.
Liu W, Zhang Y, Chen Q et al. Melatonin alleviates glucose and lipid metabolism disorders in guinea pigs caused by different
artificial light rhythms. J Diabetes Res. 2020; 2020: 4927403. doi: 10.1155/2020/4927403.
Ku H, Kim Y, Kim AL, Lee G, Choi Y, Kim B. Protective effects of melatonin in high-fat diet-induced hepatic steatosis via
decreased intestinal lipid absorption and hepatic cholesterol synthesis. Endocrinol Metab (Seoul). 2023; 38(5): 557–567.
doi: 10.3803/EnM.2023.1672.
Yang W, Tang K, Wang Y, Zhang Y, Zan L. Melatonin promotes triacylglycerol accumulation via MT2 receptor during
differentiation in bovine intramuscular preadipocytes. Sci Rep. 2017; 7(1): 15080. doi: 10.1038/s41598-017-12780-y.
de Souza CAP, Gallo CC, de Camargo LS et al. Melatonin multiple effects on brown adipose tissue molecular machinery. J
Pineal Res. 2019; 66(2): e12549. doi: 10.1111/jpi.12549.
Liu Z, Gan L, Luo D, Sun C. Melatonin promotes circadian rhythm-induced proliferation through Clock/histone deacetylase
/c-Myc interaction in mouse adipose tissue. J Pineal Res. 2017; 62(4): e12383. doi: 10.1111/jpi.12383.
Delpino FM, Figueiredo LM. Melatonin supplementation and anthropometric indicators of obesity: A systematic review and
meta-analysis. Nutrition. 2021; 91–92: 111399. doi: 10.1016/j.nut.2021.111399.
Li Z, Zheng M, Mo J et al. Single-cell RNA sequencing of preadipocytes reveals the cell fate heterogeneity induced by
melatonin. J Pineal Res. 2021; 70(3): e12725. doi: 10.1111/jpi.12725.
Biggio G, Biggio F, Talani G et al. Melatonin: from neurobiology to treatment. Brain Sci. 2021; 11(9): 1121. doi: 10.3390/
brainsci11091121.
Santos-Ledo A, Luxán-Delgado B, Caballero B et al. Melatonin ameliorates autophagy impairment in a metabolic syndrome
model. Antioxidants (Basel). 2021; 10(5): 796. doi: 10.3390/antiox10050796.
Cardinali DP, Brown GM, Pandi-Perumal SR. Melatonin’s benefits and risks as a therapy for sleep disturbances in the
elderly: current insights. Nat Sci Sleep. 2022; 14: 1843–1855. doi: 10.2147/NSS.S380465.
Tung YT, Chiang PC, Chen YL, Chien YW. Effects of melatonin on lipid metabolism and circulating irisin in Sprague-
Dawley rats with diet-induced obesity. Molecules. 2020; 25(15): 3329. doi: 10.3390/molecules25153329.
Guan Q, Wang Z, Cao J, Dong Y, Chen Y. Mechanisms of melatonin in obesity: A review. Int J Mol Sci. 2021; 23(1): 218.
doi: 10.3390/ijms23010218.
Adikwu E, Bokolo B. Melatonin and N-acetylcysteine as remedies for tramadol-induced hepatotoxicity in albino rats. Adv
Pharm Bull. 2017; 7(3): 367–374. doi: 10.15171/apb.2017.044.
Allagui MS, Hachani R, Saidi S et al. Pleiotropic protective roles of melatonin against aluminium-induced toxicity in rats.
Gen Physiol Biophys. 2015; 34(4): 415–424. doi: 10.4149/gpb_2015028.
Wang HR, Woo YS, Bahk WM. The role of melatonin and melatonin agonists in counteracting antipsychotic-induced metabolic
side effects: a systematic review. Int Clin Psychopharmacol. 2016; 31(6): 301–306. doi: 10.1097/YIC.0000000000000135.
Ghaderi A, Banafshe HR, Mirhosseini N et al. The effects of melatonin supplementation on mental health, metabolic and
genetic profiles in patients under methadone maintenance treatment. Addict Biol. 2019; 24(4): 754–764. doi: 10.1111/
adb.12650.
Uluişik D, Keskin E, Hatipoğlu D. A study on effect of melatonin in dyslipidemia caused by experimentally diabetes. TJSE.
; 21(1): 117–121. doi: 10.15314/tsed.541834.
Al-Sarraf IAK, Kasabri V, Akour A, Naffa R. Melatonin and cryptochrome 2 in metabolic syndrome patients with or without
diabetes: a cross-sectional study. Horm Mol Biol Clin Investig. 2018; 35(2). Available from: /j/hmbci.2018.35.issue-2/
hmbci-2018-0016/hmbci-2018-0016.xml. doi: 10.1515/hmbci-2018-0016.
Goyal A, Terry PD, Superak HM et al. Melatonin supplementation to treat the metabolic syndrome: a randomized controlled
trial. Diabetol Metab Syndr. 2014; 6: 124. doi: 10.1186/1758-5996-6-124.
Chojnacki C, Błońska A, Chojnacki J. The effects of melatonin on elevated liver enzymes during statin treatment. Biomed
Res Int. 2017; 2017: 3204504. doi: 10.1155/2017/3204504.
Mohammadi-Sartang M, Ghorbani M, Mazloom Z. Effects of melatonin supplementation on blood lipid concentrations: A
systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2018; 37(6 Pt A): 1943–1954. doi: 10.1016/j.
clnu.2017.11.003.
Peneva VM, Terzieva DD, Mitkov MD. Role of melatonin in the onset of metabolic syndrome in women. Biomedicines.
; 11(6): 1580. doi: 10.3390/biomedicines11061580.
Abood SJ, Abdulsahib WK, Hussain SA, Ismail SH. Melatonin potentiates the therapeutic effects of metformin in women
with metabolic syndrome. Sci Pharm. 2020; 88(2): 28. doi: 10.3390/scipharm88020028.
Sun H, Wang X, Chen J et al. Melatonin treatment improves insulin resistance and pigmentation in obese patients with
acanthosis nigricans. Int J Endocrinol. 2018; 2018: 2304746. doi: 10.1155/2018/2304746.
Boutin JA, Kennaway DJ, Jockers R. Melatonin: facts, extrapolations and clinical trials. Biomolecules. 2023; 13(6): 943.
doi: 10.3390/biom13060943.
Loloei S, Sepidarkish M, Heydarian A et al. The effect of melatonin supplementation on lipid profile and anthropometric
indices: A systematic review and meta-analysis of clinical trials. Diabetes Metab Syndr. 2019; 13(3): 1901–1910. doi:
1016/j.dsx.2019.04.043.
Celinski K, Konturek PC, Slomka M et al. Effects of treatment with melatonin and tryptophan on liver enzymes, parameters
of fat metabolism and plasma levels of cytokines in patients with non-alcoholic fatty liver disease--14 months follow up. J
Physiol Pharmacol. 2014; 65(1): 75–82. PMID: 24622832.
Ozkalayci F, Kocabas U, Altun BU, Pandi-Perumal S, Altun A. Relationship between melatonin and cardiovascular disease.
Cureus. 2021; 13(1): e12935. doi: 10.7759/cureus.12935.
Genario R, Cipolla-Neto J, Bueno AA, Santos HO. Melatonin supplementation in the management of obesity and obesityassociated
disorders: a review of physiological mechanisms and clinical applications. Pharmacol Res. 2021; 163: 105254.
doi: 10.1016/j.phrs.2020.105254.
